SG10201609184PA - Compositions and methods for extended therapy with aminopyridines - Google Patents
Compositions and methods for extended therapy with aminopyridinesInfo
- Publication number
- SG10201609184PA SG10201609184PA SG10201609184PA SG10201609184PA SG10201609184PA SG 10201609184P A SG10201609184P A SG 10201609184PA SG 10201609184P A SG10201609184P A SG 10201609184PA SG 10201609184P A SG10201609184P A SG 10201609184PA SG 10201609184P A SG10201609184P A SG 10201609184PA
- Authority
- SG
- Singapore
- Prior art keywords
- aminopyridines
- compositions
- methods
- extended therapy
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15167909P | 2009-02-11 | 2009-02-11 | |
US25956309P | 2009-11-09 | 2009-11-09 | |
US28587209P | 2009-12-11 | 2009-12-11 | |
US28895309P | 2009-12-22 | 2009-12-22 | |
US29925910P | 2010-01-28 | 2010-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201609184PA true SG10201609184PA (en) | 2016-12-29 |
Family
ID=42562065
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201609184PA SG10201609184PA (en) | 2009-02-11 | 2010-02-11 | Compositions and methods for extended therapy with aminopyridines |
SG2011057783A SG173641A1 (en) | 2009-02-11 | 2010-02-11 | Compositions and methods for extended therapy with aminopyridines |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011057783A SG173641A1 (en) | 2009-02-11 | 2010-02-11 | Compositions and methods for extended therapy with aminopyridines |
Country Status (22)
Country | Link |
---|---|
US (3) | US20120029035A1 (fr) |
JP (1) | JP2012517449A (fr) |
KR (3) | KR20180114250A (fr) |
CN (2) | CN102046174A (fr) |
AR (1) | AR075413A1 (fr) |
AU (2) | AU2010213663A1 (fr) |
BR (2) | BRPI1000030A2 (fr) |
CA (1) | CA2751581A1 (fr) |
CL (1) | CL2011001927A1 (fr) |
CO (1) | CO6440534A2 (fr) |
EA (1) | EA022755B1 (fr) |
EC (1) | ECSP11011311A (fr) |
IL (1) | IL214500A0 (fr) |
MX (1) | MX2011008485A (fr) |
NI (1) | NI201100155A (fr) |
NZ (1) | NZ595046A (fr) |
PE (1) | PE20120791A1 (fr) |
SG (2) | SG10201609184PA (fr) |
TN (1) | TN2011000403A1 (fr) |
TW (2) | TW201034665A (fr) |
UY (2) | UY32445A (fr) |
WO (2) | WO2010093838A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
US20150111930A1 (en) * | 2013-10-23 | 2015-04-23 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
AR078323A1 (es) * | 2009-09-04 | 2011-11-02 | Acorda Therapeutics Inc | Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple |
CN102442942A (zh) * | 2010-10-08 | 2012-05-09 | 天津和美生物技术有限公司 | 4-氨基吡啶的多晶型物及其制备和应用 |
EP2667869A1 (fr) * | 2011-01-28 | 2013-12-04 | Acorda Therapeutics, Inc. | Utilisation d'inhibiteurs des canaux potassiques dans le traitement d'une paralysie cérébrale |
MX2014009811A (es) * | 2012-02-13 | 2014-09-08 | Acorda Therapeutics Inc | Metodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis multiple que utilizan una aminopiridina. |
WO2014028387A1 (fr) * | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Méthodes d'amélioration de la capacité de marche chez des patients atteints de sclérose en plaques à l'aide d'une aminopyridine |
US11145417B2 (en) * | 2014-02-04 | 2021-10-12 | Optimata Ltd. | Method and system for prediction of medical treatment effect |
RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
US10172842B2 (en) | 2015-09-11 | 2019-01-08 | PharmaDax Inc. | Sustained release oral dosage form containing dalfampridine |
WO2022124946A1 (fr) * | 2020-12-10 | 2022-06-16 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Nouvelles formes polymorphes de 4-aminopyridine et leur application pharmaceutique |
CN112914884B (zh) * | 2021-01-19 | 2022-02-11 | 重庆火后草科技有限公司 | 通过稳态时长置信度测量睡眠状态下的体重值的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
US6288026B1 (en) * | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
US8007826B2 (en) * | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
US8354437B2 (en) * | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
-
2010
- 2010-02-11 KR KR1020187029188A patent/KR20180114250A/ko not_active Application Discontinuation
- 2010-02-11 SG SG10201609184PA patent/SG10201609184PA/en unknown
- 2010-02-11 UY UY0001032445A patent/UY32445A/es not_active Application Discontinuation
- 2010-02-11 NZ NZ595046A patent/NZ595046A/xx unknown
- 2010-02-11 UY UY0001032444A patent/UY32444A/es not_active Application Discontinuation
- 2010-02-11 WO PCT/US2010/023969 patent/WO2010093838A1/fr active Application Filing
- 2010-02-11 EA EA201171043A patent/EA022755B1/ru unknown
- 2010-02-11 BR BRPI1000030A patent/BRPI1000030A2/pt not_active IP Right Cessation
- 2010-02-11 KR KR1020177007639A patent/KR20170034452A/ko active Application Filing
- 2010-02-11 JP JP2011549357A patent/JP2012517449A/ja active Pending
- 2010-02-11 CN CN201080000861XA patent/CN102046174A/zh active Pending
- 2010-02-11 CN CN2010800008624A patent/CN101896182A/zh active Pending
- 2010-02-11 MX MX2011008485A patent/MX2011008485A/es not_active Application Discontinuation
- 2010-02-11 SG SG2011057783A patent/SG173641A1/en unknown
- 2010-02-11 AU AU2010213663A patent/AU2010213663A1/en not_active Abandoned
- 2010-02-11 US US13/148,231 patent/US20120029035A1/en not_active Abandoned
- 2010-02-11 BR BRPI1000031A patent/BRPI1000031A2/pt not_active Application Discontinuation
- 2010-02-11 TW TW099104403A patent/TW201034665A/zh unknown
- 2010-02-11 KR KR1020117021266A patent/KR20120000560A/ko active Application Filing
- 2010-02-11 WO PCT/US2010/023970 patent/WO2010093839A1/fr active Application Filing
- 2010-02-11 TW TW099104401A patent/TW201032809A/zh unknown
- 2010-02-11 PE PE2011001475A patent/PE20120791A1/es not_active Application Discontinuation
- 2010-02-11 CA CA2751581A patent/CA2751581A1/fr not_active Abandoned
- 2010-02-12 AR ARP100100402A patent/AR075413A1/es unknown
-
2011
- 2011-08-07 IL IL214500A patent/IL214500A0/en unknown
- 2011-08-09 NI NI201100155A patent/NI201100155A/es unknown
- 2011-08-10 TN TN2011000403A patent/TN2011000403A1/fr unknown
- 2011-08-10 CL CL2011001927A patent/CL2011001927A1/es unknown
- 2011-09-08 EC EC2011011311A patent/ECSP11011311A/es unknown
- 2011-09-09 CO CO11116663A patent/CO6440534A2/es not_active Application Discontinuation
-
2014
- 2014-11-26 US US14/555,487 patent/US20150313886A1/en not_active Abandoned
-
2016
- 2016-08-25 AU AU2016219650A patent/AU2016219650C1/en active Active
-
2017
- 2017-05-17 US US15/597,991 patent/US20170319562A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL214500A0 (en) | Compositions and methods for extended therapy with aminopyridines | |
SG2014010706A (en) | Method and composition | |
IL218212A0 (en) | Therapeutic methods and compositions | |
GB201016001D0 (en) | Composition and method | |
IL215765A0 (en) | Prion-free nanoparticle compositions and methods | |
ZA201109034B (en) | Aminopyrrolidinone derivatives and uses thereof | |
IL213974A0 (en) | Isoxazole-isoxazole and isoxazole-isothiazole derivatives | |
EP2629742A4 (fr) | Compositions de revitalisation capillaire et méthodes associées | |
EP2429584A4 (fr) | Procédés et compositions de traitement | |
GB0903299D0 (en) | Composition and methods | |
IL215932A0 (en) | Compositions and methods for treating burns | |
EP2555788A4 (fr) | Procédés et compositions pour la cardioprotection et la régénération cardiaque | |
GB201003531D0 (en) | Composition and method | |
HK1201451A1 (en) | Compositions and methods | |
GB201018650D0 (en) | Methods and compositions | |
GB201008843D0 (en) | Method and composition | |
GB0912744D0 (en) | Methods and uses | |
GB0901494D0 (en) | Compositions and Methods | |
EP2461870A4 (fr) | Compositions thérapeutiques et procédés associés | |
GB201008364D0 (en) | Composition and method | |
HK1162526A1 (en) | Glp-1 derivatives and uses thereof glp-1 | |
ZA201106583B (en) | Com[positions and methods for extended therapy with aminopyridines | |
GB201003741D0 (en) | Methods and therapeutic compositions | |
GB0907616D0 (en) | Methods and compositions | |
GB0909720D0 (en) | Compositions and methods |